Je was op zoek naar: glycopeptide (Engels - Maltees)

the active substance in xydalba, dalbavancin, is a type of antibiotic called glycopeptide.
is-sustanza attiva f’xydalba, id-dalbavancin, hija tip ta’ antibijotiku imsejjaħ glikopeptid.

pharmacotherapeutic group: antibacterials for systemic use, glycopeptide antibacterials, atc code: j01xa03
kategorija farmakoterapewtika: antibatteriċi għal użu sistemiku, antibatteriċi tat-tip glycopeptides, kodiċi atc: j01xa03

have ever had an allergic reaction to another glycopeptide antibiotic (such as vancomycin and telavancin)
qatt kellek reazzjoni allerġika għal antibijotiku glycopeptide ieħor (bħal vancomycin u telavancin)

there is no known cross-resistance between oritavancin and non-glycopeptide classes of antibiotics.
m’hemm l-ebda reżistenza inkroċjata magħrufa bejn oritavancin u klassijiet ta’ antibijotiċi mhux glycopeptide.

there is no known cross-resistance between telavancin and other non-glycopeptide classes of antibiotics.
m’hemmx reżistenza inkroċjata magħrufa bejn telavancin u klassijiet oħra ta’ antibijotiċi mhux tat-tip glycopeptides.

they inhibit the activity of transpeptidase enzymes which catalyse cross- linkage of the glycopeptide polymer units that form the cell wall.
huma jimpedixxu l- attività ta ’ l- enzimi transpeptidasi li jikkatalizzaw tagħqid imħallat ta ’ l- unitajiet ta ’ polimer glikopeptide li jiffurmaw il- ħajt taċ- ċellula.

s. aureus that exhibit high level resistance to glycopeptide antibacterial agents (grsa) are not susceptible to telavancin.
s. aureus li juru livell għoli ta’ reżistenza għal antibatteriċi tat-tip glycopeptides (grsa) mhumiex suxxettibbli għal telavancin.

due to the possibility of cross-hypersensitivity, there should be careful monitoring of patients with any history of glycopeptide hypersensitivity during and after the infusion.
minħabba possibbiltà ta’ sensittività eċċessiva inkroċjata, għandu jkun hemm monitoraġġ b’attenzjoni ta’ pazjenti bi kwalunkwe storja medika ta’ sensittività eċċessiva għal glycopeptide waqt u wara l- infużjoni.

if the isolates with higher dalbavancin mics represent stable phenotypes and are correlated with resistance to the other glycopeptides, then the likely mechanism would be an increase in the number of glycopeptide targets in nascent peptidoglycan.
jekk l-iżolati b’mics ogħla għal dalbavancin jirrappreżentaw fenotipi stabbli u huma korrelati ma’ reżistenza għall-glikopeptidi oħra, allura l-mekkaniżmu probabbli se jkun żieda fin-numru ta’ miri glikopeptidi f’peptidoglycan naxxenti.

ototoxicity has been associated with glycopeptide use (vancomycin and teicoplanin); patients who are receiving concomitant therapy with an ototoxic agent, such as an aminoglycoside, may be at increased risk.
ototossiċità ġiet assoċjata mal-użu ta’ glikopeptidi (vancomycin u teicoplanin); pazjenti li jkunu qed jirċievu terapija konkomitanti ma’ sustanza ototossika, bħal aminoglycoside, jistgħu jkunu f’riskju akbar.

whereas denmark and germany, arguing that, through the feed given to animals, this glycopeptide antibiotic produces resistance to glycopeptides used in human medicine, take the view that avoparcin presents a danger for human health;
billi d-danimarka u l-Ġermanja, filwaqt li jargumentaw illi, permezz ta' għalf mogħti lill-annimali dan l-antibijotiku glikopeptid jipproduċi reżistenza għall-glikopeptidi li jintużaw fil-mediċina tal-bniedem, jaħsbu illi l-avoparċin jippreżenta periklu għas-saħħa tal-bniedem;

the active substance in exulett, dalbavancin, is an antibiotic that belongs to the group ‘ glycopeptides’.
is- sustanza attiva f’ exulet, dalbavancin, huwa antibijotiku li jappartjeni għall- grupp tal - ‘ glikopeptidi ’.